Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D'Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S. Cassani C, et al. Among authors: secondino s. Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054. Diagnostics (Basel). 2022. PMID: 36553061 Free PMC article.
Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
Barcellini A, Charalampopoulou A, De Cecco L, Fodor A, Rabaiotti E, Candotti G, Secondino S, Facoetti A, Locati LD, Pignata S, Orlandi E, Mangili G. Barcellini A, et al. Among authors: secondino s. Life (Basel). 2022 Dec 20;13(1):6. doi: 10.3390/life13010006. Life (Basel). 2022. PMID: 36675955 Free PMC article. Review.
Granulosa cell tumors (GCTs) of the ovary: What is the role of radiotherapy?
Barcellini A, Mangili G, Fodor A, Secondino S, Zerbetto F, Charalampopoulou A, Pignata S, Orlandi E, Bergamini A. Barcellini A, et al. Among authors: secondino s. Crit Rev Oncol Hematol. 2023 Jan;181:103889. doi: 10.1016/j.critrevonc.2022.103889. Epub 2022 Nov 26. Crit Rev Oncol Hematol. 2023. PMID: 36503888 Review.
Clinical Trials of Cellular Therapies in Solid Tumors.
Secondino S, Canino C, Alaimo D, Muzzana M, Galli G, Borgetto S, Basso S, Bagnarino J, Pulvirenti C, Comoli P, Pedrazzoli P. Secondino S, et al. Cancers (Basel). 2023 Jul 19;15(14):3667. doi: 10.3390/cancers15143667. Cancers (Basel). 2023. PMID: 37509328 Free PMC article. Review.
Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Secondino S, Pedrazzoli P, Basso S, Bossi P, Bianco A, Imarisio I, Pagani A, De Cicco M, Muscianisi S, Casanova M, Morosi C, Bergamini C, Benazzo M, Cossu Rocca M, Perotti C, Baldanti F, Zecca M, Licitra LF, Comoli P. Secondino S, et al. Front Immunol. 2023 Jul 11;14:1208475. doi: 10.3389/fimmu.2023.1208475. eCollection 2023. Front Immunol. 2023. PMID: 37497213 Free PMC article.
Spermatocytic Tumor: A Review.
Secondino S, Viglio A, Neri G, Galli G, Faverio C, Mascaro F, Naspro R, Rosti G, Pedrazzoli P. Secondino S, et al. Int J Mol Sci. 2023 May 31;24(11):9529. doi: 10.3390/ijms24119529. Int J Mol Sci. 2023. PMID: 37298487 Free PMC article. Review.
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cavalieri S, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca MC, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L. Cavalieri S, et al. Among authors: secondino s. Cells. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176. Cells. 2022. PMID: 36231138 Free PMC article.
Testicular tumors in the "elderly" population.
Secondino S, Rosti G, Tralongo AC, Nolè F, Alaimo D, Carminati O, Naspro RLJ, Pedrazzoli P. Secondino S, et al. Front Oncol. 2022 Sep 16;12:972151. doi: 10.3389/fonc.2022.972151. eCollection 2022. Front Oncol. 2022. PMID: 36185182 Free PMC article. Review.
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
Lasagna A, Bergami F, Lilleri D, Percivalle E, Quaccini M, Serra F, Comolli G, Sarasini A, Sammartino JC, Ferrari A, Arena F, Secondino S, Cicognini D, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: secondino s. ESMO Open. 2022 Oct;7(5):100574. doi: 10.1016/j.esmoop.2022.100574. Epub 2022 Aug 5. ESMO Open. 2022. PMID: 36029652 Free PMC article.
67 results